MBCC | Conference

Combination of Variables May Inform Oncologists on Residual Risk After Adjuvant Therapy for Breast Cancer
March 11, 2021

Independent variables, such as the burden of disease prior to treatment, molecular prognosis, sensitivity to chemotherapy, sensitivity to endocrine therapy, and sensitivity to other treatments could be effective in predicting risk of recurrence in patients with breast cancer.

Promising Antibody-Drug Conjugates Have the Potential to Change Treatment Landscape for HER2-Negative Breast Cancer
March 10, 2021

Kevin Kalinsky, MD, MS, discussed a number of antibody-drug conjugates, detailing the prevailing data and potential trials that may change the treatment paradigm for patients with breast cancer.

Preventing and Treating Cardiotoxicity in Patients With Breast Cancer Involves Aggressive Monitoring, Management Strategies
March 09, 2021

Mandar Aras, MD, PhD, discussed the management and prevention of cardiotoxicity in patients receiving systemic therapy for breast cancer at the 38th Annual Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC.